REG - Graft Polymer (UK) - Patent Application

Graft Polymer (UK)Announcement

31/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe5078Qa&default-theme=true

RNS Number : 5078Q  Graft Polymer (UK) PLC  31 May 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

31 May 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

Further Patent Application

 

Filing of US Provisional Patent for Treatment of Mental Health Disorders

 

Graft Polymer (UK) Plc (LSE: GPL) announces that it has filed a second utility
patent application (provisional) with the United States Patent and Trademark
Office (USPTO). This application is for the use of the Company's proprietary
and patented self-nanoemulsifying drug delivery systems (SNEDDS) platform for
the delivery of drugs for the treatment of mental health disorders such as
Generalised Anxiety Disorder (GAD), Major Depressive Disorder (MDD) and
Post-Traumatic Stress Disorder (PTSD).

 

 

Patent Filing Overview

The provisional patent application, titled 'Composition and methods for mental
health disorders using a self-nanoemulsifying drug delivery systems (SNEDDS)',
covers the innovative application of Graft Polymer's SNEDDS platform to
enhance the bioavailability, pharmacokinetics and stability of therapeutics
used in the treatment of health disorders such as GAD, MDD and PTSD, many of
which have poor solubility leading to suboptimal drug delivery and posing an
obstacle to successful formulation. This approach aims to leverage the
Company's existing advanced biopolymer expertise to address significant unmet
medical needs in addiction therapy.

 

 

Strategic Significance

The filing of this patent follows the announcement, by the Company, on 28 May
2024 relating to the filing of a similar utility patent application
(provisional) for the treatment of substance use disorders. It marks further
progress in the Company's strategic focus on the healthcare industry,
following the disposal of its industrial plastic manufacturing unit, Graft
Polymer D.O.O, as announced on 3 May 2024. This disposal has enabled the
Company to focus its attention and resources on its Graft Bio division, which
represents, in the Directors' opinion, strong prospectivity through its
intellectual property (IP), licensing agreements, and sales contracts.

 

 

Anthony Tennyson, CEO commented:

"We are delighted to announce further progress in leveraging our existing
biopolymer intellectual property for additional important healthcare
applications with substantial unmet medical needs."

 

 

Enquiries

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director

Email: anthonytennyson@graftpolymer.com

Yifat Steuer, CFO and Executive Director

Email: yifat@graftpolymer.com

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

 +44 (0) 20 3328 5656

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAPBDGDUSUXDGSG